Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.

2020Background: BEV + radiotherapy/temozolomide (RT/TMZ) improves progression-free survival (PFS) (vs placebo [PBO] + RT/TMZ) in newly diagnosedGBM, but this does not translate into an OS benefit (AVAglio/NCT00943826). Data from recurrent GBM (Tabouret, Neuro Oncol 2014, 2015) suggest that MMP9 and MMP2 plasma levels may predict BEV-related tumor response and correlate with improved OS. Evaluation of MMP9 and MMP2 as potential biomarkers for patients likely to derive OS benefit from BEV is needed. We present data from a retrospective analysis of AVAglio, which assessed whether MMP9 baseline levels predicted OS benefit from BEV in newly diagnosed GBM. Methods: MMP9 and MMP2 levels were assessed (ELISA; RD BEV n=283). Post-hoc analysis and PFS/OS multivariate models including MMP9–treatment interactions were carried out. Results: MMP9 distribution at baseline was comparable between arms...